KALV Form 4: 3,750 RSU Grant to CDO; Sell-to-Cover of 2,362 Shares at $13.22
Rhea-AI Filing Summary
KalVista Pharmaceuticals insider filing: Christopher Yea, Chief Development Officer, received a grant of 3,750 restricted stock units (RSUs) on 08/21/2025 that convert 1-for-1 into common shares upon settlement for no consideration. After the grant, the reporting person beneficially owned 133,243 shares. On 08/22/2025 he sold 2,362 shares at an average price of $13.2228 to satisfy tax-withholding obligations from the RSU settlement, leaving 130,881 shares beneficially owned. The RSUs vest quarterly with 1/16th vesting on each quarterly anniversary beginning 05/21/2025, subject to continued service. The sale was described as a routine "sell to cover" for taxes and not a discretionary trade.
Positive
- Transparent disclosure of RSU grant, vesting schedule, and sell-to-cover tax sale
- Insider retains substantial holding after the transaction: 130,881 shares beneficially owned
Negative
- None.
Insights
TL;DR: Routine RSU grant and a sell-to-cover tax sale; modest net dilution to insider holdings, limited investor impact.
The Form 4 records a standard equity compensation event: a grant of 3,750 RSUs that settle one-for-one into common stock, increasing the reporting person’s beneficial holdings to 133,243 shares. A one-day subsequent sale of 2,362 shares at $13.2228 was disclosed as a sell-to-cover to satisfy tax withholding, which is typical for RSU settlements and not indicative of a voluntary liquidity event. The vesting schedule (1/16th quarterly beginning 05/21/2025) implies incremental future share issuances tied to continued service. Overall this is a routine insider compensation disclosure with neutral implications for control or corporate governance.
TL;DR: Compensation-related transaction following standard procedures; no governance red flags evident in the filing.
The filing shows compliance with Section 16 reporting for an officer-level RSU award and a sell-to-cover tax settlement. The transaction was reported timely and includes vesting terms and the tax-sale explanation. There is no evidence here of concentrated insider selling beyond tax obligations and no change in officer status. For governance review, the disclosed vesting cadence and settlement-for-no-consideration terms are conventional and transparent.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,362 | $13.2228 | $31K |
| Exercise | Restricted Stock Unit | 3,750 | $0.00 | -- |
| Exercise | Common Stock | 3,750 | $0.00 | -- |
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. 1/16th of the total restricted stock units subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025, subject to continued service through each vesting date.
